14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NVS vs GILD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Gilead Sciences Inc (GILD) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas GILD carries 40.1/100 (SELL) at $169.09 (16.6x Forward P/E, 38.2% operating margin).
Composite vs. Pillar Nuance: While NVS currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. GILD 40.1/100 SELL), GILD captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (38.2% vs. 34.0% operating margin) and revenue trajectory (+6.8% vs. +4.7% YoY).
Defensive Composite Rating Caution: Although GILD compares more favorably head-to-head, both NVS (41.5/100 SELL) and GILD (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs GILD. Trailing 12-month operating profitability (NVS 34.0% vs GILD 38.2%) and valuation multiples (NVS 16.2x vs GILD 16.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($16.7B)
90D Engineering Disclosures0 Published
GILD Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $208.3B market capitalization and 38.2% operating margin.
OpEx & R&D Reinvestment41.7% of Rev ($12.9B)
90D Engineering Disclosures0 Published
Investor FAQ NVS vs GILD Key Questions & Quantitative Answers
As of Nov 16, 2026, Gilead Sciences Inc (GILD) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas GILD carries 40.1/100 (SELL) at $169.09 (16.6x Forward P/E, 38.2% operating margin). Composite vs. Pillar Nuance: While NVS currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. GILD 40.1/100 SELL), GILD captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (38.2% vs. 34.0% operating margin) and revenue trajectory (+6.8% vs. +4.7% YoY). Defensive Composite Rating Caution: Although GILD compares more favorably head-to-head, both NVS (41.5/100 SELL) and GILD (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
GILD leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with GILD at +6.8% YoY revenue growth and -20.2% YoY earnings growth on $31.0B TTM revenue (79.9% gross margin, 38.2% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $31.0B for GILD. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 41.7% of Rev ($12.9B) (0 disclosures) for GILD.
GILD screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas GILD trades at 16.6x Forward P/E, 17.0x Trailing P/E, 2.29x PEG, and 7.4x EV/Revenue (44.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus GILD (-22.4% ROE) capital efficiency.
In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, GILD carries 29.3% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.63x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.34β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.